Early efficacy of rTMS intervention at week 2 predicts subsequent responses at week 24 in schizophrenia in a randomized controlled trial

被引:1
|
作者
Ye, Suzhen [1 ]
Guan, Xiaoni [2 ]
Xiu, Meihong [2 ]
Wu, Fengchun [3 ,4 ,5 ,6 ]
Huang, Yuanyuan [3 ,4 ,5 ,6 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Rehabil, Wenzhou, Peoples R China
[2] Peking Univ, Beijing HuiLongGuan Hosp, HuiLongGuan Clin Med Sch, Beijing, Peoples R China
[3] Guangzhou Med Univ, Affiliated Brain Hosp, Dept Psychiat, Guangzhou, Peoples R China
[4] Guangdong Engn Technol Res Ctr Translat Med Mental, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Key Lab Neurogenet & Channelopathies Guangdong Pro, Guangzhou, Peoples R China
[6] Guangzhou Med Univ, Minist Educ China, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Schizophrenia; rTMS; Randomized controlled trial; Cognitive functions; Efficacy; TRANSCRANIAL MAGNETIC STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; BRAIN-STIMULATION; DOUBLE-BLIND; COGNITIVE DEFICITS; MEMORY DYSFUNCTION; TOP-DOWN; DISORDER; CONNECTIVITY;
D O I
10.1016/j.neurot.2024.e00392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique for modulating cortical activities and improving neural plasticity. Several studies investigated the effects of rTMS, etc., but the results are inconsistent. This study was designed to examine whether rTMS applied on the left dorsolateral prefrontal cortex (l-DLPFC) showed an effect on improving cognitive deficits in SZ and whether the early efficacy could predict efficacy at subsequent follow-ups. Cognitive ability was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scale at baseline, weeks 2, 6, and 24. We found a significant interaction between time (weeks 0, 2, 6, and 24) and intervention on immediate memory and RBANS total scores (p = 0.02 and p = 0.04), indicating that both 10-Hz and 20-Hz rTMS stimulations had a delayed beneficial effect on immediate memory in SZ. Moreover, we found that 20-Hz rTMS stimulation, but not 10-Hz rTMS improved immediate memory at week 6 compared to the sham group (p = 0.029). More importantly, improvements in immediate memory at week 2 were positively correlated with improvements at week 24 (beta = 0.461, t = 3.322, p = 0.002). Our study suggests that active rTMS was beneficial for cognitive deficits in patients with SZ. Furthermore, efficacy at week 2 could predict the subsequent efficacy at 24-week follow-up.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial
    Tang, Yiguo
    Wu, Yulu
    Li, Xiaojing
    Hao, QinJian
    Deng, Wei
    Yue, Weihua
    Yan, Hao
    Zhang, Yamin
    Tan, Liwen
    Chen, Qi
    Yang, Guigang
    Lu, Tianlan
    Wang, Lifang
    Yang, Fude
    Zhang, Fuquan
    Yang, Jianli
    Li, Keqing
    Lv, Luxian
    Tan, Qingrong
    Zhang, Hongyan
    Ma, Xin
    Li, Lingjiang
    Wang, Chuanyue
    Ma, Xiaohong
    Zhang, Dai
    Yu, Hao
    Zhao, Liansheng
    Ren, Hongyan
    Wang, Yingcheng
    Zhang, Guangya
    Li, Chuanwei
    Du, Xiangdong
    Hu, Xun
    Li, Tao
    Wang, Qiang
    CURRENT NEUROPHARMACOLOGY, 2023, 21 (02) : 424 - 436
  • [2] A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial
    Li, Xue
    Yuan, Xiuxia
    Kang, Yulin
    Pang, Lijuan
    Liu, Yafei
    Zhu, Qiyue
    Lv, Luxian
    Huang, Xu-Feng
    Song, Xueqin
    JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 126 : 81 - 91
  • [3] Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial
    Stentebjerg-Olesen, Marie
    Ganocy, Stephen J.
    Findling, Robert L.
    Chang, Kiki
    DelBello, Melissa P.
    Kane, John M.
    Tohen, Mauricio
    Jeppesen, Pia
    Correll, Christoph U.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2015, 24 (12) : 1485 - 1496
  • [4] Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial
    Marie Stentebjerg-Olesen
    Stephen J. Ganocy
    Robert L. Findling
    Kiki Chang
    Melissa P. DelBello
    John M. Kane
    Mauricio Tohen
    Pia Jeppesen
    Christoph U. Correll
    European Child & Adolescent Psychiatry, 2015, 24 : 1485 - 1496
  • [5] Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Goldman, Robert
    Loebel, Antony
    Cucchiaro, Josephine
    Deng, Ling
    Findling, Robert L.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 516 - 525
  • [6] Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4-week randomized placebo controlled study
    Schneider, Alan L.
    Schneider, Terry L.
    Stark, Harry
    BRAIN STIMULATION, 2008, 1 (02) : 106 - 111
  • [7] Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial
    Kauer-Sant'Anna, Marcia
    Frey, Benicio N.
    Fijtman, Adam
    Loredo-Souza, Ana C.
    Dargel, Aroldo A.
    Pfaffenseller, Bianca
    Wollenhaupt-Aguiar, Bianca
    Gazalle, Fernando K.
    Colpo, Gabriela D.
    Passos, Ives C.
    Bucker, Joana
    Walz, Julio C.
    Jansen, Karen
    Mendes Cereser, Keila M.
    Burke Bridi, Kelen P.
    Soria, Lisiane dos Santos
    Kunz, Mauricio
    Pinho, Michele
    Kapczinski, Natalia S.
    Goi, Pedro D.
    Magalhaes, Pedro V. S.
    Reckziegel, Ramiro
    Burque, Renan K.
    Cardoso, Taiane de Azevedo
    Kapczinski, Flavio
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (04) : 502 - 510
  • [8] Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial
    Boggs, Douglas L.
    Kelly, Deanna L.
    McMahon, Robert P.
    Gold, James M.
    Gorelick, David A.
    Linthicum, Jared
    Conley, Robert R.
    Liu, Fang
    Waltz, James
    Huestis, Marilyn A.
    Buchanan, Robert W.
    SCHIZOPHRENIA RESEARCH, 2012, 134 (2-3) : 207 - 210
  • [9] Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
    Turner, Alyna
    McGrath, John J.
    Dean, Olivia M.
    Dodd, Seetal
    Baker, Andrea
    Cotton, Susan M.
    Scott, James G.
    Kavanagh, Bianca E.
    Ashton, Melanie M.
    Walker, Adam J.
    Brown, Ellie
    Berk, Michael
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2019, 17 (02) : 297 - 307
  • [10] Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Saito, Takuya
    Sugimoto, Saori
    Sakaguchi, Reiko
    Nakamura, Hiroshi
    Ishigooka, Jun
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) : 12 - 23